You are here
Orphan Designation for Multiple System Atrophy Drug
Treatment Improves Motor Function, Preserves Neurons
January 31, 2019
Prana Biotechnology Ltd has received orphan drug status for its lead molecule PBT434 for the treatment of Multiple System Atrophy (MSA). It is the first time the FDA has granted orphan designation for this degenerative neurological disorder.
PBT434 prevents the accumulation of alpha-synuclein, protects neurons, and improves motor function in a widely accepted animal model of MSA. Clustered forms of alpha-synuclein are a hallmark of Parkinsonian conditions, including this one. Currently, there are no approved treatments for MSA.
Prana is conducting a phase 1 clinical trial of PBT434 which it expects to be completed in 2019.
Source: Prana Biotechnology Ltd, January 31, 2019
Recent Headlines
More research is needed to confirm the finding
Study shows "complex genetic risk architecture"
Study says yes, interventions cuts need for meds
Review of 18 studies finds that medium doses have the strongest effects
Research suggests that stress mitigation could be an effective intervention strategy
Children, parents with ADHD benefit from parenting intervention
Meeting 'zombie cells' along the way
A new 'road map' might make it easier
First such procedure in the U.S.